Matrixx Touts Survey Showing Pharmacists Support Zinc Remedies
This article was originally published in The Tan Sheet
Matrixx Initiatives furthers its strategy to restore consumer trust in its troubled Zicam brand with a survey showing most pharmacists recommend zinc-based remedies for a cold.
You may also be interested in...
A federal judge in Arizona objects to Matrixx Initiatives' proposed settlement of economic injury claims in 18 class-action filings. The Zicam maker said Sept. 3 it is working to resolve the procedural issues and still expects to finalize the settlement - totaling up to $35,000 (1"The Tan Sheet" Aug. 23, 2010). In an 2order filed Aug. 26, Judge Frederick Martone of the U.S. District Court for the District of Arizona rejects and denies the stipulation and joint request for dismissal without prejudice. Joining the economic injury claims with another case against Matrixx in a Chicago federal court would circumvent an earlier decision by a panel on multidistrict litigation, which rejected centralizing all actions in the Chicago court, Martone says. Scottsdale, Ariz.-based Matrixx faces hundreds of personal injury suits from consumers claiming they suffer anosmia from use of zinc-containing intranasal Zicam swab products
Matrixx Initiatives faces long odds against convincing FDA to withdraw a warning letter concerning the firm's Zicam intranasal products, food and drug lawyers say after the firm's request was rejected a second time
Narrowly interpreting the definition of serious adverse events - compared to FDA's approach - is already costing Matrixx Initiatives at least $10 million dollars with the recall of its intranasal Zicam products